Navigation Links
MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
Date:12/21/2010

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced completion of the LEVADEX open-label safety trial.  The Company has now completed the final trial necessary to support a New Drug Application (NDA) for LEVADEX and plans to submit an NDA in the first half of 2011.  LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 clinical development for the acute treatment of migraine.

"We are pleased to have completed the LEVADEX clinical program. This clinical trial completes a comprehensive 505(b)(2) clinical development program which evaluated the efficacy, safety, pharmacokinetics and pharmacodynamics of LEVADEX in approximately 1,000 patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "In 2010, we announced that a second Phase 3 trial would not be necessary for our NDA submission, completed and announced successful results from a pharmacokinetics trial in smokers, a pharmacodynamics trial evaluating pulmonary artery pressure and a thorough QT trial, and we have now completed our open-label safety trial."  

The 12 month open-label, safety extension of the Phase 3 FREEDOM-301 trial was designed to evaluate overall safety of LEVADEX over six and 12 months of exposure.  In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  In this trial no drug-related serious adverse events were reported.

The Company anticipates presenting safety results from the trial at an upcoming scientific conference.  

About LEVADEX™LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has b
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
2. Lotus Pharmaceuticals Announces Change of Directors
3. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
6. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. John A. MacPhee Resigns From Strativa Pharmaceuticals
8. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
9. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Reportlinker.com announces that a new market research report ... and Taiwanese Markets for Minimally Invasive Spinal Devices ... The market for MIS spinal devices in the ... at a fast pace, albeit at different rates in ... China , where MIS spinal fusion ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
Breaking Medicine Technology:Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2
... SEOUL, South Korea, Feb. 16, 2012   ,The ... the largest health care provider festival, is ... This Exhibition, for enhancing a national ... of hospital-related industry, is hosted by Korea ...
... Therapeutics, Inc. (NASDAQ: HALO ) today announced the ... its common stock, including 1,020,000 shares sold pursuant to the ... underwriter. All of the shares were offered by Halozyme at ... proceeds to Halozyme from this offering were approximately $81.8 million, ...
Cached Medicine Technology:To Take a Glance Cutting Edge Medicine Equipment! 'The 28th International Medical & Hospital Equipment Show' 2To Take a Glance Cutting Edge Medicine Equipment! 'The 28th International Medical & Hospital Equipment Show' 3Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 2Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 3
(Date:9/3/2014)... 03, 2014 "What can you say about ... "Margaret and Hillary," Book Eight in the Margaret of ... published by Wyston Books, Inc . These novels narrate ... in the richest town in America. , In this thriller, ... helps to investigate a student’s murder plot. Her fears increase ...
(Date:9/2/2014)... Autumn is well under way and famous review ... with worldwide people. Recently, it has made a ... http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost are the best ... 2002 HostGator has been known as a top ... reliability remains with it today. It is offering ...
(Date:9/2/2014)... today,s concentrated pot might be risky business for ... University. The study is the first to demonstrate ... THC. , Psychology professor Rebecca Craft showed ... are at least 30 percent more sensitive than ... active ingredient in cannabis. Females also develop tolerance ...
(Date:9/2/2014)... 2014 http://topcreatinemonohydrate.com/ , a ... obtain the latest information about muscle and fitness ... focuses mainly on testosterone and creatine ... their workout capacity and improve their athletic performance. ... Creatine Monohydrate, Muscle Advance Creatine is one of ...
(Date:9/2/2014)... Illinois (PRWEB) September 02, 2014 ... Chief Executive Officer and Chief Information Officer Strategy ... Carlton Chicago. , Becker's Hospital Review Chief Executive ... together hospital and health system Chief Executive Officers, ... hospital and health system executives through high-quality ...
Breaking Medicine News(10 mins):Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3Health News:Creatine Monohydrate Reviews Site TopCreatineMonohydrate.com Announces its Launch 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4
... An article appearing in the January issue of The Journal ... cancers (GISTs) are likely to be ineffective for// patients with ... reported by investigators at the Mayo Clinic Cancer Center, who ... help patients with high grade renal cell carcinoma. "While this ...
... are developing a hands-free frame, which may help stroke patients ... ,Stroke is a leading cause of adult disability in England ... ,Existing frames require the person to hold them ... cannot use these, and often need two people to support ...
... Research Center has reported that maintaining the current recommended ... of cardiovascular disease. The researcher has asked the ... patients less than the recommended levels by aggressive blood ... is used to monitor the average amount of blood ...
... way of treating psychological disorders. Carl Rogers introduced this technique ... lot of questions about this technique. But it was one ... patients from a different perspective. ,It was contradictory ... this therapy is not widely accepted by many psychologists. ...
... can do to people. High-fat diets cause many patients' problems. ... to know what they consume. ,Now, new rules on ... trans fats, which plug arteries, and have been linked to ... ,Trans fats are a result of manufacturers adding hydrogen ...
... or obese have a greater risk of developing Alzheimer’s, the ... researchers // has claimed. ,The research team ... Cowan University in Western Australia - say that being obese ... have found a link between body mass index (BMI) and ...
Cached Medicine News:Health News:New Gastric Cancer Drug Unlikely to Benefit Kidney Cancer Patients 2Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... of the MYOHANDY family are probably ... MYOQUICK - SystemPLUS line. Based on ... systems of the ISA 100x EP ... ISA 1002 EP) , 4 channels ...
Medicine Products: